SEC Form 4 · accession 0001193125-26-338420
Attovia Therapeutics, Inc. · ATTO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Attovia Therapeutics, Inc.
Officer — President and CEO · Director
Period of report
Aug 4, 2026
Accepted (ET)
Aug 6, 2026 · 5:11 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002058707
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $17.00 | Aug 4, 2026 | A | 538,300 | A | — | Aug 3, 2036 | Common Stock | 538,300 | 538,300 | D |
Explanation of responses
- F125% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.